Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Align Technology, Inc. (ALGN) vs Domino's Pizza, Inc. (DPZ) Price & Performance

Align Technology, Inc.Trade
Domino's Pizza, Inc.Trade

Price performance (Past 24H)

Key statistics

Align Technology, Inc. vs Domino's Pizza, Inc. — how do they compare? Align Technology, Inc. trades at $171.82 (market cap $12.29B), while Domino's Pizza, Inc. trades at $354.79 (market cap $11.82B). The key difference: Align Technology, Inc. and Domino's Pizza, Inc. are close in size by market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.

ALGNDPZ
Market Cap
$12.29B$11.82B
Sector
HealthConsumer Cyclical
52-Week High
$197.51$467.30
52-Week Low
$124.88$282.89
Enterprise Value
$11.30B$16.78B
Dividend Yield
2.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Align Technology, Inc.

ALGN trades at $176.04, up 1.37% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported record Q2 2026 revenue of $1.06 billion, driven by strong clear aligner volume growth. Analyst sentiment is positive, with 73% recommending buy, and institutional activity shows mixed positioning amid strategic initiatives like board changes and patent wins in China.

The outlook remains favorable due to solid fundamentals and international expansion, but risks include competitive pressures in digital dentistry and reliance on North American market stability. Earnings growth and margin improvements are key catalysts, though valuation multiples near five-year lows suggest potential upside if execution continues.

Domino's Pizza, Inc.

Domino's Pizza (DPZ) trades at $347.85, down 0.88% on the day, with mixed technical signals showing neutral overall momentum. The company reported three consecutive quarterly EPS misses but maintains strong profitability with 11.86% net margins and positive revenue growth. Recent news highlights product innovation with the launch of individual-sized pizzas and digital platform enhancements to drive customer engagement.

Wall Street maintains a bullish stance with 54% buy ratings and a $371.67 price target, representing 7% upside potential. Key risks include elevated debt levels, competitive pressures, and consumer spending sensitivity. The stock offers value through consistent dividends and operational efficiency, though near-term execution on sales growth remains critical.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Align Technology, Inc.

Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).

Read more on ALGN

About Domino's Pizza, Inc.

Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.

Read more on DPZ